2024/09/05 / Erste Group Research |
Health Care sector with attractive risk/reward profile Rating changes: Novartis, Royal Bank of Canada, Pfizer, Alimentation Couche-Tard, Cadence Design Systems, Intel The prospects for a medium-term rise in the global stock market index are intact. Corporate sales will rise by around +3.5% this year. The consensus estimate for earnings growth in 2024 is an increase of +6.4%. Next year, earnings growth will rise to +12.6%. The expected P/E ratio 2024 of the global equity market index is 19.8x and the global dividend yield is 1.9%. The valuation is reasonable given the positive growth prospects. Profit growth in the most important countries in the emerging markets varies greatly. The forecast earnings growth of Indian companies is +10.1% (y/y) for 2024 and +13% (y/y) for 2025. The global recommendation list includes India's ICICI Bank as an attractive long-term buy recommendation. The earnings growth of Indian companies is higher than that of Chinese companies. Earnings growth of +7.9% (y/y) is forecast for these companies for 2024 and +7.5% (y/y) for 2025. Novartis: High profit growth of +20% y/y in 2Q24, positive outlook for 2H24 Royal Bank of Canada: 2Q24: Net interest income up 16% y/y, adjusted ROE at 16.4% Intel: Quality problems and high debt, negative risk/reward profile |
![]() |
Author | Erste Group Research |
Date | 2024/09/05 |
Language | ![]() |
Product name | Recommendation List |
Topic in focus | Equities |
Economy in focus | Germany, Japan, United Kingdom, United States |
Currency in focus | British Pound, Euro, US Dollar |
Sector in focus | Automobiles & Parts, Banks, Basic Resources, Chemicals, Construction & Material, Financial Services, Food & Beverage, Health Care, Industrial Goods & Services, Insurance, Media, Oil & Gas, Personal & Household Goods, Retail, Technology, Telecommunications, Travel & Leisure, Utilities |
Download |
Name | ISIN | # Erste Group products |
Walt Disney | US2546871060 | 0 |
Walmart | US9311421039 | 0 |
Volkswagen | DE0007664039 | 4 |
Visa | US92826C8394 | 0 |
Vinci | FR0000125486 | 0 |
Vertex Pharmaceuticals | US92532F1003 | 0 |
Verizon | US92343V1044 | 0 |
Vale | BRVALEACNOR0 | 0 |
UnitedHealth Group | US91324P1021 | 0 |
Unilever | GB00B10RZP78 | 0 |
UniCredit | IT0005239360 | 0 |
UBS | CH0244767585 | 0 |
Toyota Motor | JP3633400001 | 0 |
TotalEnergies | FR0000120271 | 0 |
Tokyo Electron | JP3571400005 | 0 |
Thermo Fisher Scientific | US8835561023 | 0 |
Tesla | US88160R1014 | 0 |
Tencent | KYG875721634 | 0 |
Taiwan Semiconductor | TW0002330008 | 0 |
T-Mobile US | US8725901040 | 0 |
Starbucks | US8552441094 | 0 |
Southern Co | US8425871071 | 0 |
Siemens | DE0007236101 | 0 |
Shell | GB00B03MLX29 | 0 |
ServiceNow | US81762P1021 | 0 |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer